Plain-English translation of NCT06812858 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing PD-1 inhibitors—a type of immune-boosting medication—as a maintenance (or "keep-going") treatment after stem cell transplant in patients with classical Hodgkin lymphoma that has returned or stopped responding to initial chemotherapy. The goal is to see if this medication can help prevent the cancer from coming back and improve how long patients stay cancer-free. Right now, more than half of patients who receive a stem cell transplant for this type of lymphoma still experience the cancer returning, so researchers are looking for better ways to prevent relapse.
Even after stem cell transplant—a standard intensive treatment for hard-to-treat Hodgkin lymphoma—most relapses happen within the first two years, and current options for preventing this are limited. This medication offers a potentially gentler and more effective maintenance strategy than existing treatments, which sometimes cause serious side effects that force patients to stop.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive maintenance doses of the immune-boosting medication after your stem cell transplant, with the goal of preventing your lymphoma from returning. The study will monitor you at multiple medical centers to track how well the medication works, how long you stay cancer-free, and what side effects you experience. Your doctors will use imaging scans and blood tests to follow your progress over time.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
Kazakhstan
Russia